Table 1

Percent distribution of selected characteristics at diagnosis in 1,204 women with invasive breast cancer
All women Younger women Older women
(ages 35–49 y) (ages 50–64 y)
White Black Pa White Black Pa White Black Pa
n=681 n=523 n=345 n=272 n=336 n=251
Study site 0.01 0.07 0.09
 Los Angeles 66.7 73.2 64.9 71.7 68.5 74.9
 Detroit 33.3 26.8 35.1 28.3 31.6 25.1
Age at diagnosis, years 0.004 <0.001
 35-39 21.4 14.2 42.3 27.2 - -
 40-44 15.9 19.5 31.3 37.5 - -
 45-49 13.4 18.4 26.4 35.3 - -
 50-54 18.7 17.6 - - 37.8 36.7 0.42
 55-59 14.5 16.4 - - 29.5 34.3
 60-64 16.2 14.0 - - 32.7 29.1
ER status <0.001 0.05 <0.001
 ER- 36.9 48.8 46.4 54.4 27.1 42.6
 ER+ 63.1 51.2 53.6 45.6 72.9 57.4
PR status <0.001 <0.001 <0.001
 PR- 38.5 52.4 42.6 54.0 34.2 50.6
 PR+ 61.5 47.6 57.4 46.0 65.8 49.4
HER2 status 0.16 0.98 0.04
 HER2- 83.3 80.1 81.2 81.3 85.4 78.9
 HER2+ 16.7 19.9 18.8 18.7 14.6 21.1
Subtypes defined by ER/PR/HER2 <0.001 0.12 <0.001
 TN 23.8 33.5 30.4 39.0 17.0 27.5
 Luminal A 59.5 46.7 50.7 42.3 68.5 51.4
 Luminal B 9.8 10.3 11.0 9.9 8.6 10.8
 HER2-enriched 6.9 9.6 7.8 8.8 6.0 10.4
p53 status <0.001 0.003
 p53- 77.0 65.8 72.5 61.0 0.003 81.6 70.9
 p53+ 23.0 34.2 27.5 39.0 18.4 29.1
Subtypes defined by ER/PR/HER2/p53 <0.001 0.03 <0.001
 TN/p53- 14.4 16.6 18.0 18.8 10.7 14.3
 TN/p53+ 9.4 16.8 12.5 20.2 6.3 13.2
 Luminal A/p53- 49.9 37.7 41.5 31.3 58.6 44.6
 Luminal A/p53+ 9.5 9.0 9.3 11.0 9.8 6.8
 Luminal B/p53- 8.1 6.0 8.4 5.2 7.7 6.8
 Luminal B/p53+ 1.8 4.4 2.6 4.8 0.9 4.0
 HER2-enriched/p53- 4.6 5.5 4.6 5.9 4.5 5.2
 HER2-enriched/p53+ 2.4 4.0 3.2 2.9 1.5 5.2
Stage <0.001 0.007 0.001
 Localized 63.1 51.1 56.5 45.6 69.9 57.0
 Non-localized 36.9 49.0 43.5 54.4 30.1 43.0
Grade <0.001 0.006 <0.001
 Low 12.5 8.6 9.6 6.6 15.5 10.8
 Intermediate 63.1 53.0 58.6 49.3 67.9 57.0
 High 24.4 38.4 31.9 44.1 16.7 32.3

aP ascertained from Pearson χ2 test. Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER, human epidermal growth factor receptor; TN, triple negative. Note: TN = ER-/PR-/HER2-, Luminal A = ER+ or PR+ plus HER2-, Luminal B = ER+ or PR+ plus HER2+, HER2-enriched = ER-/PR-/HER2+.

Ma et al.

Ma et al. BMC Cancer 2013 13:225   doi:10.1186/1471-2407-13-225

Open Data